ONE HOME FOR SITES
LIVE

Serial Number

98583104

Owner

IQVIA Inc.

Attorney

CYNTHIA JOHNSON WALDEN

Filing Date

Jun 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ONE HOME FOR SITES Trademark

Serial Number: 98583104

ONE HOME FOR SITES is a trademark filed by IQVIA Inc. on June 4, 2024. The trademark is classified under Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

IQVIA Inc.

100 IMS Drive
Parsippany, NJ 07054

Entity Type: 03

Trademark Details

Filing Date

June 4, 2024

Registration Date

Not Registered

Goods & Services

Business consulting, administrative, management, and information services in the field of clinical trials; Regulatory submission management, namely, assisting others in preparing and filing applications for new drugs, biologics, and devices with governmental regulatory bodies; Providing business consulting services in the field of clinical research, and clinical trials; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug, biologics, and device approval; Recruitment services, namely, advertising clinical trials, recruiting patients, and placing patients for participation in clinical trials for testing of drugs, biologics, and devices; Providing a website and online portal featuring business information in the pharmaceutical and life sciences fields; Providing independent review of clinical trials for business purposes; Database management and data processing services; Business networking and online business networking services; Management and compilation of business directories and registries; Online business directories featuring information on clinical trials, clinical trial professionals, and patients in clinical trials; all aforementioned services relating to clinical trials; none of the aforementioned services relating to at home care

Scientific research in the field of clinical trials, pharmaceuticals, biologics, and devices; Scientific research, namely, conducting clinical trials and providing documentation for submission to regulatory authorities in connection therewith; Providing scientific research information in the field of clinical trials, pharmaceuticals, biologics, and devices; Pharmaceutical drug, biologic, and device development services; Providing scientific research information in the field of clinical trials, pharmaceuticals, biologics, and devices via online searchable database; Research and development of new products for others; Consulting services in the field of contract clinical research and contract product development; Consulting services for others in the field of design, planning, and implementation project management of clinical trials; Providing scientific research information to pharmaceutical and biotechnology companies; Providing an online non-downloadable database in the field of clinical trials for scientific research purposes; Online non-downloadable software, software as a service (SaaS) featuring software for, platform as a service (PAAS) featuring software for, and online non-downloadable cloud-based software providing clinical trial, pharmaceutical, medical, healthcare, and life sciences information and analysis; Online non-downloadable software, software as a service (SaaS) featuring software for, platform as a service (PAAS) featuring software for, and online non-downloadable cloud-based software accessing, collecting, managing, tracking, analyzing, and reporting data in the clinical trial, pharmaceutical and life sciences fields; Online non-downloadable software, software as a service (SaaS) featuring software for, platform as a service (PAAS) featuring software for, and online non-downloadable cloud-based software for scientific research and clinical trials; Online non-downloadable software, software as a service (SaaS) featuring software for, platform as a service (PAAS) featuring software for, and online non-downloadable cloud-based software for collecting, managing, and analyzing clinical trial data; Scientific and new product development research, consulting, and support services; Contract clinical research and contract product developments; all aforementioned services relating to clinical trials; none of the aforementioned services relating to at home care

Filing History

NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Aug 9, 2026 GNS1
SUBSEQUENT FINAL EMAILED
Aug 9, 2026 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Aug 9, 2026 CFRC
JURISDICTION RESTORED TO EXAMINING ATTORNEY
May 7, 2026 JURT
NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Feb 21, 2026 GEA1
ACTION DENYING REQ FOR RECON E-MAILED
Feb 21, 2026 GECD
ACTION CONTINUING FINAL - COMPLETED
Feb 21, 2026 CNCF
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 2025 CRFA
ASSIGNED TO LIE
Dec 11, 2025 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 28, 2025 ERFR
EX PARTE APPEAL-INSTITUTED
Nov 28, 2025 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Nov 28, 2025 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Nov 28, 2025 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 26, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 26, 2025 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 28, 2025 GNFN
FINAL REFUSAL E-MAILED
May 28, 2025 GNFR
FINAL REFUSAL WRITTEN
May 28, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 31, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 30, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 30, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 30, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 16, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2024 NWOS
NEW APPLICATION ENTERED
Jun 4, 2024 NWAP